61 filings
8-K
MYOK
MyoKardia, Inc.
17 Nov 20
Termination of a Material Definitive Agreement
4:45pm
8-K
MYOK
MyoKardia, Inc.
5 Nov 20
MyoKardia Reports Third Quarter 2020 Financial Results
4:35pm
8-K
MYOK
MyoKardia, Inc.
5 Oct 20
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
6:47am
8-K
MYOK
MyoKardia, Inc.
4 Aug 20
MyoKardia Reports Second Quarter 2020 Financial Results
4:38pm
8-K
MYOK
MyoKardia, Inc.
24 Jun 20
Submission of Matters to a Vote of Security Holders
4:11pm
8-K
o43mtvxewu
14 May 20
MyoKardia Announces Proposed Public Offering of Common Stock
5:24pm
8-K
y24oll1zype47qd5rof
11 May 20
Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo
9:26am
8-K
6bfv32s51amo
6 May 20
MyoKardia Reports First Quarter 2020 Financial Results
4:34pm
8-K
wvsv 4knbf5gicqp
30 Mar 20
MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten
5:13pm
8-K
zjahv53u
26 Mar 20
MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic
8:46am
8-K
1tfe1f
27 Feb 20
MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results
4:25pm
8-K
r03 cnebxwbin
3 Jan 20
Entry into a Material Definitive Agreement
4:18pm
8-K
fhzqw55qri
12 Nov 19
MyoKardia Announces Positive Topline Data from its Phase 2MAVERICK-HCM Clinical Trial of Mavacamten
9:01am
8-K
anz9q57858m749n
4 Nov 19
MyoKardia Reports Third Quarter 2019 Financial Results
12:00am
8-K
poe hykrmp7hw0rwycg7
4 Oct 19
Departure of Directors or Certain Officers
5:16pm
8-K
he1n nvkam
10 Sep 19
Other Events
4:06pm
8-K
v6v6nzl3qj 54tt
7 Aug 19
MyoKardia Reports Second Quarter 2019 Financial Results
4:26pm
8-K
y4mjxr9pnihztx
18 Jul 19
Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
4:01pm
8-K
agyxy83neju qn0h0fpn
18 Jun 19
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
8kvbzgo1lrg
9 May 19
MyoKardia Reports First Quarter 2019 Financial Results
4:32pm